Creative Medical Technology Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Date: October 29, 2025
Reporting Period: Current Report (Event Date: October 29, 2025)
Business Context: The Company entered into a warrant exercise inducement transaction to raise capital for working capital and general corporate purposes.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, or margins. The following transaction-specific financial data is disclosed:
- Gross Proceeds: Approximately $4.2 million from the exercise of existing warrants.
- Exercise Price (Existing Warrants): $3.75 per share.
- Shares Exercised: 1,116,136 shares.
- Financial Advisory Fee: 8% of aggregate gross proceeds.
- Legal Expense Reimbursement: $40,000.
- Net Proceeds: Not explicitly stated; gross proceeds are before deducting fees.
Material Changes and Transaction Details
The Company executed a material definitive agreement involving the following changes:
- Warrant Exercise: Holders agreed to exercise 1,116,136 existing warrants issued on March 6, 2025.
- Inducement Warrants Issued: The Company issued new warrants to purchase 2,790,340 shares of common stock.
- Inducement Warrant Terms:
- Exercise price: $3.75 per share, subject to reduction to the lowest VWAP during the five trading days following issuance.
- Exercisability: Contingent upon stockholder approval required by Nasdaq rules; exercisable for five years post-approval.
- Additional Adjustments:
- Exercise price reduction for certain warrants issued in May 2022 and December 2021 to $4.73 per share.
- Issuance of warrants to purchase up to 279,036 shares to a consenting investor.
Guidance, Outlook, and Risks
Use of Proceeds: Net proceeds will be used for working capital and general corporate purposes.
Regulatory Requirements:
- Stockholder approval is required before the Inducement Warrants become exercisable.
- The Company must file a resale registration statement on Form S-3 within 30 days of closing.
- The Inducement Warrants and underlying shares are unregistered and cannot be sold in the U.S. except pursuant to an exemption or effective registration.
- Transaction success depends on obtaining necessary stockholder approvals.
Investor Verification Checklist
- Verify the status of the stockholder approval required for the Inducement Warrants to become exercisable.
- Confirm the filing of the Form S-3 resale registration statement within the 30-day window.
- Calculate the exact net proceeds after deducting the 8% advisory fee and $40,000 legal reimbursement.
- Review the impact of the exercise price reduction on warrants issued in 2021 and 2022.
- Monitor the Company's common stock VWAP to determine the potential adjusted exercise price of the Inducement Warrants.